Novavax, Inc. (NVAX)
After hours: 07:59PM EDT
| Previous close | 169.74 |
| Open | 170.00 |
| Bid | 161.09 x 1200 |
| Ask | 161.82 x 800 |
| Day's range | 160.33 - 170.74 |
| 52-week range | 76.59 - 331.68 |
| Volume | 3,147,185 |
| Avg. volume | 5,099,066 |
| Market cap | 12B |
| Beta (5Y monthly) | 1.62 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -9.51 |
| Earnings date | 10 May 2021 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 264.20 |
- Motley Fool
5 of the Fastest-Growing Stocks On the Planet
For instance, AMC Entertainment (NYSE: AMC) reported 2,252% revenue growth in its most recent quarter. Last year at this time, the COVID-19 lockdown was crushing a lot of stocks, with revenues dropping to near-zero for many companies. While some of these stocks are "turn around" stories, all of the stocks in this article have strong financials and are way safer than AMC.
- Motley Fool
Why Shares of Moderna, Novavax, and Ocugen Are Falling Today
Shares of Moderna (NASDAQ: MRNA) are off by 3.4%; Novavax (NASDAQ: NVAX) is down 5.1%; and Ocugen's (NASDAQ: OCGN) stock is in the red by a jaw-dropping 13.3%, all as of 3:34 p.m. EDT Friday. The U.S. Food and Drug Administration (FDA) might delay the decision on Moderna's jab for adolescents due to safety issues, according to a report from the Wall Street Journal.
- Yahoo Finance Video
NIH Director on FDA ‘being careful’ in clearing Moderna vaccine for kids 12-17
Dr. Francis Collins, Outgoing NIH Director, joins Yahoo Finance’s Anjalee Khemlani to discuss Covid-19 vaccine production, drug development research, and misinformation surrounding Covid-19 vaccines.
